Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

78
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
78
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

63
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
63
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

83
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
83
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

550
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
550
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

122
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
122
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

91
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PowerNovo2: A generative flow-based approach to non-autoregressive de novo peptide sequencing.

PLoS computational biology·2026
Same author

[Diagnostic significance of ubiquitin C-terminal hydrolase L1 in patients with mine-blast traumatic brain injury].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

Changes in the proteomic profile of athletes' plasma associated with exercise intensity.

Scientific reports·2026
Same author

Genomic Characterization of a Novel Yezo Virus Revealed in <i>Ixodes pavlovskyi</i> Tick Virome in Western Siberia.

Viruses·2025
Same author

Tailored Crystallization Dynamics for Efficient and Stable DMSO-Free Tin Perovskite Solar Cells.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Incubation of Horseradish Peroxidase near 50 Hz AC Equipment Promotes Its Disaggregation and Enzymatic Activity.

Micromachines·2025

Related Experiment Video

Updated: Nov 24, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.

Kristina A Malsagova1, Tatyana V Butkova1, Arthur T Kopylov1

  • 1Biobanking Group, Branch of Institute of Biomedical Chemistry "Scientific and Education Center", 109028 Moscow, Russia.

Pharmaceutics
|December 23, 2020
PubMed
Summary

Pharmacogenomics (PGx) uses genetic information to guide drug therapy decisions, improving treatment for non-responsive patients. Understanding PGx results is key for effective clinical application and personalized medicine.

Keywords:
genetic polymorphismpersonalized medicinepharmacogenetic testpharmacogenetics

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.7K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K

Related Experiment Videos

Last Updated: Nov 24, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.7K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.0K

Area of Science:

  • Pharmacogenomics and personalized medicine.

Background:

  • Pharmacogenomics (PGx) investigates the link between an individual's genome and their response to drugs.
  • PGx testing offers physicians a valuable tool for optimizing treatment strategies, especially for patients with non-standard responses.
  • Despite growing interest, the precise mechanisms connecting genetic variations to drug responses remain incompletely understood.

Purpose of the Study:

  • To provide a comprehensive overview of pharmacogenomics (PGx).
  • To discuss the practical aspects of PGx testing efficiency in clinical settings.
  • To address critical issues including personal data security and health safety related to PGx.

Main Methods:

  • Literature review of current clinical applications and research in pharmacogenomics.
  • Analysis of the challenges and opportunities in implementing PGx testing.
  • Discussion of ethical and safety considerations in personalized medicine.

Main Results:

  • Pharmacogenomics enables tailored therapeutic decisions by considering individual genetic profiles.
  • Effective implementation relies on clinicians' ability to interpret PGx test results accurately and consistently.
  • Key considerations for widespread adoption include test efficiency, data privacy, and patient safety.

Conclusions:

  • Pharmacogenomics holds significant promise for advancing personalized medicine and improving patient outcomes.
  • Standardized interpretation and understanding of PGx results are crucial for clinical success.
  • Addressing data security and health safety concerns is essential for the responsible integration of PGx into healthcare.